Imatinib dose optimization based on therapeutic drug monitoring in Chinese patients with chronic-phase chronic myeloid leukemia.

Fang ChengFang ZengQiang LiZheng CuiYilin ChenWei-Ming LiYu Zhang

Published in: Cancer (2022)

Imatinib concentration was closely associated with clinical response and adverse reactions, suggesting that dose optimization based on TDM might achieve beneficial clinical outcomes. Dose reduction based on TDM is feasible and safe for patients exhibiting optimal response, which could improve adverse reactions.

Keyphrases

chronic myeloid leukemia
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
emergency department
adverse drug
patient reported outcomes